KRAS Binders Hidden in Nature.
Andreas BergnerXiaoling CockcroftGerhard FischerAndreas GollnerWolfgang HelaRoland KousekAndreas MantoulidisLaetitia J MartinMoriz MayerBarbara MüllauerGabriella SiszlerBernhard WolkerstorferDirk KesslerDarryl B McConnellPublished in: Chemistry (Weinheim an der Bergstrasse, Germany) (2019)
Natural products have proven to be a rich source of molecular architectures for drugs. Here, an integrated approach to natural product screening is proposed, which uncovered eight new natural product scaffolds for KRAS-the most frequently mutated oncogenic driver in human cancers, which has remained thus far undrugged. The approach combines aspects of virtual screening, fragment-based screening, structure-activity relationships (SAR) by NMR, and structure-based drug discovery to overcome the limitations in traditional natural product approaches. By using our approach, a new "snugness of fit" scoring function and the first crystal-soaking system of the active form of KRASG12D , the protein-ligand X-ray structures of a tricyclic indolopyrrole fungal alkaloid and an indoloisoquinolinone have been successfully elucidated. The natural product KRAS hits discovered provide fruitful ground for the optimization of highly potent natural-product-based inhibitors of the active form of oncogenic RAS. This integrated approach for screening natural products also holds promise for other "undruggable" targets.